Company Overview and News

 
Bandhan Bank, ZEEL, IB Ventures results

2018-10-09 thehindubusinessline
Four actively-tracked companies from different fields of business — Bandhan Bank, Indiabulls Ventures, Uttam Galva Steels and Zee Enertainment Enterprises — will declare their quarterly results for the period ended September 2018 on Wednesday. Bandhan Bank’s asset quality will come under sharp focus. The Kolkata-based bank had reported a 48 per cent jump in net profit at ₹482 crore for the quarter ended June 30, compared to ₹327 crore in the same period last year.
532960 IBVENTURES 513216 IDBLZ UTTAMSTL

 
81 firms under NSE ASM framework

2018-08-17 freepressjournal.in
New Delhi : As many as 81 firms have come under the Additional Surveillance Measure (ASM) framework of the NSE, according to the latest data available with the exchange.
ESL SHILPI AMKD MOREPENLAB EMAMIINFRA AMTEKAUTO ZENITHEXPO 531723 532513 532997 UTTAMVALUE IDBLZ 531543 512553 532775 GTLINFRA 534976 532960 JINDWORLD 533207 RADICO KSK 500254 IBVENTURES 533264 ZENTEC 533389 539207 TVSELECT VMART 532497 533218 533339 JPINFRATEC 500288 STAMPEDE 520077 MANPASAND

 
D-Street Buzz: Metals loose shine with JSPL down 6%; Jubilant Foodworks hits fresh 52-week high

2018-08-10 moneycontrol
The Indian benchmark indices continues to trade in the red this Friday afternoon, but managed to regain some lost grounds with the Sensex down 67 points at 37,956 while the Nifty shed 15 points at 11,454.
SANOFI 532617 PRMQY 533155 532778 JUBLFOOD IDBLZ 532215 CADILAHC 505200 532960 532321 AXISBANK JBLWY 500674 HEROMOTOCO EICHERMOT 509488 YESBANK EXIDEIND ECQRY HINDALCO GRAPHITE AXB IBVENTURES IBN JETAIRWAYS CANFINHOME 532648 YYBKY 511196 PEL CDLYY AXBKY 500182 HNDNF AXBA EXQDY ICICIBANK BATAINDIA 532174 HRTQY 500302 LITL 500086 500043 500440

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...